Application deadline: 4 Sep 2019, 16:00 GMT+1
Aim
The overarching aim of the UK-Japan collaborative initiative in infectious diseases is to provide bi-lateral support to biomedical and health researchers in the UK and Japan that will allow them to forge lasting collaborations. This initiative aims to strengthen existing links or foster new links that add value to research taking place in both countries. This is expected to be achieved by facilitating exchange and catalysing innovative synergy amongst collaborators and is particularly aimed at those who are in the early stages of their careers. Therefore it is expected that applications will be made by eligible early career researchers or by established researchers who explicitly wish to encourage the career development of their postdoctoral researchers. It is hoped that the partnerships established through these awards will lead to the development of long-term collaborative research programmes that will be competitive for international funding.
Objective
The objective is to provide bilateral support for up to eight, catalytic, innovative collaborative partnerships between researchers from Japan and UK. These will enable important synergy between researchers with shared or complementary interests.
Scope
This call aims to support early career researchers develop fruitful international collaborations in the field of infectious diseases. Within this broad field we would particularly like to encourage applications which tackle the more challenging issues of infectious diseases including 1) priority viral outbreak pathogens; 2) research providing mechanistic insight into latency/persistence/resistance in infectious diseases; and 3) research exploring the host infection interface, particularly at key barrier sites eg blood-brain barrier.
Research areas of interest include:
- the pathogenesis of lethal viruses, such as the Ebola virus, Lassa virus, or tick-borne viruses
- mechanistic insight on latent and persistent infections
- exploration of host infection interface eg central nervous system infections by blood-brain barrier failure, transplacental infections or mucosal-gut barrier
- drug resistant pathogens
- development of new treatment measures, therapeutic agents, vaccines or therapeutic strategies concerning any of the above.
For more information, or to apply, visit the call website.